FN-1501 |
FN-1501 |
Phase Ⅰ |
China Pharmaceutical University, Fosun Pharma |
Leukemia |
Details
|
LY-2457546 |
LY-2457546 |
Phase Ⅰ |
Lilly |
Acute myeloid Leukemia (AML) |
Details
|
Tozasertib |
VX-680; MK-0457,VX680,MK0457 |
Phase Ⅱ |
Vertex, Merck Sharp & Dohme |
Solid tumours, Leukemia |
Details
|
Crenolanib Besylate |
ARO-002; ARO-002-26; CP-868596; CP-868596-26; IND-112201 |
Phase Ⅲ |
Pfizer, AROG Pharmaceuticals |
Gastrointestinal stromal tumors (GISTs), Acute myeloid Leukemia (AML) |
Details
|
L-21649 |
L-21649; L-000021649 |
Phase Ⅰ |
Merck Sharp & Dohme |
Solid tumours, Acute myeloid Leukemia (AML) |
Details
|
Flysyn |
4G8-SDIEM,4G8 SDIEM,4G8SDIEM |
Phase Ⅱ |
Synimmune |
Acute myeloid Leukemia (AML) |
Details
|
CTx-0294886 |
AMP-886; CTx-294886 |
Preclinical |
Cancer Therapeutics, Amplia Therapeutics Limited, Cancer Research Technology |
Pulmonary fibrosis, Cancer |
Details
|
JNJ-28312141 |
JNJ-28312141,JNJ28312141,JNJ 28312141 |
Phase Ⅰ |
Johnson & Johnson |
Solid tumours, Rheumatoid arthritis (RA) |
Details
|
AM-5992 |
AM-5992 |
Preclinical |
Amgen |
Acute myeloid Leukemia (AML) |
Details
|
Famitinib Malate |
SHR-1020 |
Phase Ⅲ |
Jiangsu Hengrui Medicine |
Non small cell lung cancer (NSCLC), Colorectal cancer |
Details
|
E-6201 |
E-6201,E6201 |
Phase Ⅱ |
Eisai, QuintilesIMS, Strategia Therapeutics, Spirita Oncology |
Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia(CMML), Acute lymphoblastic leukaemia (ALL) |
Details
|
XY0206 |
XY-0206 |
Phase Ⅰ |
Shijiazhuang Yiling Pharmaceutical, Nanjing University of Chinese Medicine |
Acute myeloid Leukemia (AML) |
Details
|
SKLB-1028 |
SKLB-1028 |
Phase Ⅱ |
China Shijiazhuang Pharmaceutical Group/CSPC, Sichuan University |
Acute myeloid Leukemia (AML) |
Details
|
Amuvatinib |
MP-470; HPK-56,MP470,HPK56 |
Phase Ⅱ |
Astex Pharmaceuticals |
Small cell lung cancer (SCLC) |
Details
|
AMG-427 (Amgen) |
AMG-427 |
Phase Ⅰ |
Amgen |
Acute myeloid Leukemia (AML) |
Details
|
Silvestrol |
|
Preclinical |
Ohio State University, National Cancer Institute |
Cancer |
Details
|
SU-014813 |
SU-014813; SU-14813 |
Phase Ⅱ |
Pfizer |
Breast cancer |
Details
|
FF-10101 |
FF-10101-01; FF-10101; FF-10101 succinate |
Phase Ⅱ |
FUJIFILM Corporation, Nagoya University |
Acute myeloid Leukemia (AML) |
Details
|
KW-2449 |
KW-2449,KW2449 |
Phase Ⅱ |
Kyowa Hakko Kirin |
Acute myeloid Leukemia (AML), Hematological cancer |
Details
|
CEP-751 |
CEP-751; KT-6587 |
Phase Ⅰ |
Kyowa Hakko Kirin, Teva |
Prostate cancer |
Details
|
MRX-2843 |
UNC-2025; MRX-2843; UNC-2371 |
Phase Ⅰ |
University of North Carolina, Meryx, University of Colorado at Denver, Betta |
Solid tumours |
Details
|
Tandutinib |
MLN-0518; MLN-518; CT-53518,MLN0518,MLN518,CT53518 |
Phase Ⅱ |
Takeda |
Renal cell carcinoma, Acute myeloid Leukemia (AML) |
Details
|
SKI-G-801 |
SKI-G-801; G-801; G-749 Hydrochloride |
Phase Ⅰ |
Oscotec |
Acute myeloid Leukemia (AML) |
Details
|
FLX-925 |
FLX-925; AMG-925,FLX925,AMG925 |
Phase Ⅰ |
Amgen, RAPT Therapeutics |
Acute myeloid Leukemia (AML) |
Details
|
Ningetinib Tosylate |
CT-053-PTSA; CT-053 |
Phase Ⅱ |
HEC Pharm |
Non small cell lung cancer (NSCLC), Renal carcinoma |
Details
|
Pacritinib |
ONX-0803; SB-1518,ONX0803,SB1518 |
Phase Ⅲ |
Concert, S*BIO, CTI BioPharma, Baxter |
Myelofibrosis, Acute myeloid Leukemia (AML) |
Details
|
QBH-196 |
QBH-196 |
Phase Ⅰ |
Shenyang Pharmaceutical University |
Gastric cancer |
Details
|
HYML-122 |
CHMFL-FLT3-122; HYML-122 |
Phase Ⅰ |
Hefei Cosource Pharmaceuticals, Hefei Institute of Physical Science, Chinese Academy of Sciences |
Acute myeloid Leukemia (AML) |
Details
|
Dovitinib |
CHIR-258; GFKI-258; CHIR-258LC; TKI-258; NVP-TKI258,GFKI258,CHIR258,TKI258 |
Phase Ⅲ |
Novartis |
Renal cell carcinoma, Solid tumours |
Details
|
SGI-1776 |
SGI-1776; SG-0407,SGI1776,SG0407 |
Phase Ⅰ |
Astex Pharmaceuticals |
Prostate cancer, Non-Hodgkin's lymphoma (NHL) |
Details
|
QLNC-3A6 Di-Maleate |
|
Phase Ⅰ |
Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical |
Solid tumours |
Details
|
AT-9283 |
AT-9283,AT9283 |
Phase Ⅱ |
Otsuka |
Multiple myeloma (MM) |
Details
|
AKN-028 |
AKN-028; BVT-II; BVT-63628 ,AKN028,BVTII,BVT63628 |
Phase Ⅱ |
Akinion |
Acute myeloid Leukemia (AML) |
Details
|
LOXO-102 |
LOXO-102; LOXO-103; LOXO-104 |
Preclinical |
Array BioPharma, Lilly |
Cancer |
Details
|
IMC EB10 |
|
Phase Ⅰ |
Lilly |
Acute granulocytic leukemia |
Details
|
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) |
CDX-301 |
Phase Ⅱ |
Amgen, Celldex, National Cancer Institute |
Non small cell lung cancer (NSCLC) |
Details
|
CG-806 |
CG-026806; CG-806 |
Phase Ⅰ |
CrystalGenomics, Aptose |
hematological malignancies, Non-Hodgkin's lymphoma (NHL) |
Details
|
Lestaurtinib |
A-154475.0; CEP-701; KT-5555; SP-924; SPM-924 |
Phase Ⅲ |
Kyowa Hakko Kirin, Cephalon |
Acute lymphoblastic leukaemia (ALL) |
Details
|
AMG-553 |
AMG-553,AMG 553,AMG553 |
Phase Ⅰ |
Amgen |
Acute myeloid Leukemia (AML) |
Details
|
Hydroxychloroquine/Sorafenib |
|
Phase Ⅰ |
VG Life Sciences |
Solid tumours, Ovarian cancer |
Details
|
HM-43239 |
|
Phase Ⅱ |
Hanmi |
Acute myeloid Leukemia (AML) |
Details
|
SC-71710 |
SC-71710; 4SC-203 |
Phase Ⅰ |
4SC AG, ProQinase |
Acute myeloid Leukemia (AML) |
Details
|
Donafenib Tosylate |
CM-4307 |
Phase Ⅲ |
Zelgen Biosciences |
Thyroid cancer, Colorectal cancer |
Details
|
XL-999 |
XL-999; EXEL-0999 |
Phase Ⅱ |
Exelixis, GlaxoSmithKline, Symphony Evolution |
Non small cell lung cancer (NSCLC), Renal cell carcinoma, Colorectal cancer, Multiple myeloma (MM), Acute myeloid Leukemia (AML), Ovarian cancer |
Details
|
Sorafenib/MG-005 |
MGD-1509 |
Phase Ⅱ |
Metagone Biotech, The General Hospital of the Three Armies |
Solid tumours |
Details
|
PLX-7486 |
PLX-7486; PLX7486-TsOH |
Phase Ⅱ |
Daiichi Sankyo |
Solid tumours, Pancreatic cancer |
Details
|
Clifutinib Besylate |
|
Phase Ⅰ |
HEC Pharm |
Acute myeloid Leukemia (AML) |
Details
|
DBPR-114 |
|
Phase Ⅰ |
National Health Research Institutes |
Cancer |
Details
|
AC-886 |
AC-886 |
Phase Ⅰ |
Daiichi Sankyo |
Acute myeloid Leukemia (AML) |
Details
|
MAX-40279 |
MAX-40279-001; MAX-40279-01; Max-1; Max-40279 |
Phase Ⅰ |
Maxinovel Pharmaceuticals |
Acute myeloid Leukemia (AML) |
Details
|
NMS-03592088 |
NMS-03592088; NMS-P088 |
Phase Ⅱ |
Nerviano Medical Sciences |
Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) |
Details
|
Mivavotinib |
TAK-659 |
Phase Ⅱ |
Takeda |
Diffuse large B cell lymphoma |
Details
|
Imidacrine |
C-1311; NSC-645809; XF-02; XLS-002 |
Phase Ⅱ |
University of Bradford, BTG plc, Antisoma |
Breast cancer, Colorectal cancer |
Details
|
CT-1578 |
SB-1578; CT-1578; ONX-0805,SB1578,CT1578,ONX0805 |
Phase Ⅰ |
S*BIO, CTI BioPharma, Onyx Pharmaceutical |
Rheumatoid arthritis (RA) |
Details
|
AG-2034 |
AG-2034; AGL-2034 |
Phase Ⅰ |
Yissum |
Solid tumours |
Details
|
SEL-24 |
MEN-1703;SEL-24;SEL-24 program;SEL-24-1;SEL-24-B489 |
Phase Ⅱ |
Selvita, Menarini |
Acute myeloid Leukemia (AML) |
Details
|
Zotiraciclib |
SB-1317; TG-02 |
Phase Ⅱ |
S*BIO, Tragara, Lee's Pharm, Zhaoke Oncology |
Glioblastoma, Anaplastic astrocytoma |
Details
|